Spinally develops implantable spinal cord stimulation technologies designed to improve neuromodulation efficacy through direct access to spinal circuits. The company’s flagship platform, FuturaLead, is an intrathecal spinal cord stimulation lead placed directly on the surface of the spinal cord. Its approach departs from conventional epidural stimulation by enabling closer and more precise neural interfacing. Spinally positions its technology within regulated clinical and neurosurgical care contexts.

The technology places stimulation electrodes within the intrathecal space, allowing direct interaction with spinal cord tissue. This proximity enables lower stimulation thresholds and more selective activation of neural pathways compared to epidural approaches. The system supports closed-loop neuromodulation through evoked compound action potential (ECAP) sensing, enabling real-time adjustment of stimulation based on neural response. This feedback-driven architecture is designed to improve consistency and therapeutic precision.

Spinally targets patients requiring spinal cord stimulation for chronic pain and other neurological indications. The FuturaLead system is intended for use in specialized clinical settings under professional supervision. Its positioning reflects broader efforts to advance spinal neuromodulation through more precise electrode placement and adaptive, closed-loop control.